Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date

References

• ThamYCLiXWongTYQuigleyHAAungTChengCYGlobal prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysisOphthalmology2014121112081209024974815
   PubMed Web of Science ®Google Scholar
• NemesureBHonkanenRHennisAWuSYLeskeMCBarbados Eye Studies GroupIncident open-angle glaucoma and intraocular pressureOphthalmology2007114101810181517583352
   PubMed Web of Science ®Google Scholar
• SchwartzKBudenzDCurrent management of glaucomaCurr Opin Ophthalmol2004152119126 pii15021223
   PubMedGoogle Scholar
• WeinrebRNKhawPTPrimary open-angle glaucomaLancet200436394221711172015158634
   PubMed Web of Science ®Google Scholar
• RaoPVPattabiramanPPKopczynskiCRole of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside researchExp Eye Res2017158233227593914
   PubMed Web of Science ®Google Scholar
• BucoloCSalomoneSDragoFReibaldiMLongoAUvaMGPharmacological management of ocular hypertension: current approaches and future prospectiveCurr Opin Pharmacol2013131505523069477
   PubMed Web of Science ®Google Scholar
• SambharaDArefAAGlaucoma management: relative value and place in therapy of available drug treatmentsTher Adv Chronic Dis201451304324381726
   PubMedGoogle Scholar
• LinCWShermanBMooreLADiscovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucomaJ Ocul Pharmacol Ther2018341–2405128609185
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120630
   Google Scholar
• ChoyMPharmaceutical Approval UpdateP T201843420522729622939
   PubMedGoogle Scholar
• SturdivantJMRoyaltySMLinCWDiscovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucomaBioorg Med Chem Lett201626102475248027072905
   PubMed Web of Science ®Google Scholar
• NakajimaENakajimaTMinagawaYShearerTRAzumaMContribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyesJ Pharm Sci200594470170815682386
   PubMed Web of Science ®Google Scholar
• RenRLiGLeTDKopczynskiCStamerWDGongHNetarsudil increases outflow facility in human eyes through multiple mechanismsInvest Ophthalmol Vis Sci201657146197620927842161
   PubMed Web of Science ®Google Scholar
• RaoVPEpsteinDLRho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucomaBioDrugs200721316717717516712
   PubMed Web of Science ®Google Scholar
• WangRFWilliamsonJEKopczynskiCSerleJBEffect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyesJ Glaucoma2015241515425535688
   PubMed Web of Science ®Google Scholar
• KielJWKopczynskiCCEffect of AR-13324 on episcleral venous pressure in Dutch belted rabbitsJ Ocul Pharmacol Ther201531314615125756366
   PubMed Web of Science ®Google Scholar
• LiGMukherjeeDNavarroIVisualization of conventional outflow tissue responses to netarsudil in living mouse eyesEur J Pharmacol2016787203127085895
   PubMed Web of Science ®Google Scholar
• SerleJBKatzLJMcLaurinETwo phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)Am J Ophthalmol201818611612729199013
   PubMed Web of Science ®Google Scholar
• BacharachJDubinerHBLevyBKopczynskiCCNovackGDAR-13324-CS202 Study GroupDouble-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressureOphthalmology2015122230230725270273
   PubMed Web of Science ®Google Scholar
• LewisRALevyBRamirezNFixed-dose combination of AR-13324 and latanoprost: A double-masked 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. [- 3]. (- 1468-2079(Electronic); - 0007-1161-(Linking))
   Google Scholar
• LevyBRamirezNNovackGDKopczynskiCOcular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteersAm J Ophthalmol201515955.e1
   Web of Science ®Google Scholar
• UehataMIshizakiTSatohHCalcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertensionNature199738966549909949353125
   PubMed Web of Science ®Google Scholar
• HonjoMTaniharaHImpact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucomaJpn J Ophthalmol201862210912629445943
   PubMed Web of Science ®Google Scholar
• SugiyamaTShibataMKajiuraSEffects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbitsInvest Ophthalmol Vis Sci2011521646920720232
   PubMed Web of Science ®Google Scholar
• KitaokaYKitaokaYKumaiTInvolvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retinaBrain Res20041018111111815262212
   PubMed Web of Science ®Google Scholar
• SagawaHTerasakiHNakamuraMA novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult catsExp Neurol20072051230240 pii17359977
   PubMed Web of Science ®Google Scholar
• FujimotoTInoueTOhiraSInhibition of rho kinase induces antioxidative molecules and suppresses reactive oxidative species in trabecular meshwork cellsJ Ophthalmol2017 Article ID 759814023
   Web of Science ®Google Scholar
• SleathBBlalockSCovertDThe relationship between glaucoma medication adherence, eye drop technique, and visual field defect severityOphthalmology20111181223982402 https://www.clinicalkey.es/playcontent/1-s2.0-S016164201100456821856009
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther200123812961310 pii11558866
   PubMed Web of Science ®Google Scholar
• TannaAPJohnsonMRho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular HypertensionOphthalmology2018711 Epub ahead of print29351793
   PubMed Web of Science ®Google Scholar
• YuanYCallMKYuanYDexamethasone induces cross-linked actin networks in trabecular meshwork cells through noncanonical wnt signalingInvest Ophthalmol Vis Sci201354106502650923963164
   PubMed Web of Science ®Google Scholar
• FujimotoTInoueTKamedaTInvolvement of RhoA/Rho-associated kinase signal transduction pathway in dexamethasone-induced alterations in aqueous outflowInvest Ophthalmol Vis Sci201253117097710822969074
   PubMed Web of Science ®Google Scholar
• Aerie Pharmaceuticals, IncPrescribing information for Rhopressa Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdfAccessed September 26, 2018
   Google Scholar